2 completed, 1 not yet recruiting, 1 terminated, 1 withdrawn. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Terminated 1, Withdrawn 1 |
Follow Locally Advanced Soft Tissue Sarcoma: new trials by email Literature Review of Locally Advanced Soft Tissue Sarcoma trials Research Report on Locally Advanced Soft Tissue Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma. Anlotinib and bempegaldesleukin - Locally Advanced Soft Tissue Sarcoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 46 | 2025-10-01 | 2025-09-05 |
| Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas Lurbinectedin, Radiotherapy, Non-investigational surgery - Locally Advanced Soft Tissue Sarcoma | Phase 1 / Phase 2 | Withdrawn | University of California, San Francisco | 2024-10-31 | 2024-11-18 | |
| Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas Sirolimus Albumin-bound Nanoparticles, Pazopanib hydrochloride - Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma | Phase 1 / Phase 2 | Terminated | University of Washington | 19 | 2019-04-01 | 2025-04-30 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 164 | 2015-08-13 | 2023-10-17 |
| Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma INNO-206, Doxorubicin - Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma | Phase 2 | Completed | ImmunityBio, Inc. | 126 | 2012-01-11 | 2024-05-29 |
Sarcoma (3) · Bone Neoplasms (1) · Histiocytoma, Malignant Fibrous (1) · Liposarcoma (1) · Neoplasm Metastasis (1)
Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Connective and Soft Tissue (3) · Bone Diseases (1) · Histiocytoma (1) · Musculoskeletal Diseases (1) · Neoplasms by Site (1) · Neoplasms, Adipose Tissue (1) · Neoplasms, Connective Tissue (1) · Neoplasms, Fibrous Tissue (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
CTLA-4 Antigen (1) · DOXO-EMCH (1) · Doxorubicin (1) · Ipilimumab (1) · Nivolumab (1) · PM 01183 (1) · Radiotherapy (1) · anlotinib (1) · bempegaldesleukin (1) · pazopanib (1)
ImmunityBio, Inc. (1) · National Cancer Institute (NCI) (1) · The First Affiliated Hospital with Nanjing Medical University (1) · University of California, San Francisco (1) · University of Washington (1)
United States (3) · Australia (1) · China (1) · Hungary (1) · India (1) · Romania (1) · Russia (1) · Ukraine (1)
Daniel Levitt, M.D., Ph.D. (1) · Lee Cranmer, MD (1) · Sandra P D'Angelo (1) · Sant Chawla, M.D. (1) · Sheng Zhang (1) · Varun Monga, MD (1)
PMID 26378637, PMID 29370992, PMID 39343511
U10CA180821 (1)